Vetigenics was established on foundational licenses with the University of Pennsylvania (UPenn) and is advancing its existing pipeline candidates internally and through collaborations with industry partners.
The Company seeks:
Strategic collaborations to further utilize the depth and breadth of its proprietary phage display libraries such as target discovery and development.
Industry, academic and government collaborations to generate validated, fully canine reagents to support pre-clinical evaluation of novel human immunotherapies using canine animal models.
Partnerships to expand its core platform technology to include other companion animal species including cats and horses.